Company Shanghai Allist Pharmaceuticals Co., Ltd.

Equities

688578

CNE100005XJ7

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Holdings

Company contact information

Sector

Sales per Business

Sales per region

Ratings for Shanghai Allist Pharmaceuticals Co., Ltd.

EPS Revisions

Annual profits - Rate of surprise

Sector Bio Therapeutic Drugs

SHANGHAI ALLIST PHARMACEUTICALS CO., LTD.

End-of-day quote Shanghai S.E. Other stock markets 23:00:00 18/06/2024 BST			5-day change	1st Jan Change
62.7 ^CNY	-0.79%		-0.43%	+50.50%

06-17	Shanghai Allist Pharmaceuticals Co., Ltd.(SHSE:688578) added to Shanghai Stock Exchange Health Care Sector Index	CI
05-09	Abbisko Cayman Unit's Cancer Drug To Be Clinically Tested in Combination with Shanghai Allist's Furmonertinib	MT

Shanghai Allist Pharmaceuticals Co Ltd is a China-based company focusing on the field of tumor treatment. The Company has built a research and development pipeline in the field of small molecule targeted drugs for non-small cell lung cancer. The Company has established a complete new drug research and development system, covering all aspects of lead drug discovery and optimization, candidate drug evaluation and establishment, drug preclinical and clinical research, drug registration and application, industrialization and commercialization. The Company has a number of research pipeline projects under development, such as vometinib. Its drugs are used in the fields of blood pressure reduction, anti-tumor, anti-diabetic and gastric acid related diseases.

Number of employees: 1,044

CNY in Million	2022	Weight	2023	Weight	Delta
Anti-tumor 98.0 %	790	99.9 %	1,978	98.0 %	+150.22%
Technical Licensing 2.0 %	1	0.1 %	41	2.0 %	+6,442.52%
Other Business 0.0 %	0	0.0 %	0	0.0 %	+9.71%

CNY in Million	2022	Weight	2023	Weight	Delta
China 98.2 %	791	100.0 %	1,983	98.2 %	+150.68%
Overseas 1.8 %	-	-	35	1.8 %	-

Managers	Title	Age	Since
Jin Hao Du CEO	Chief Executive Officer	70	21/03/04
Feng Xu BRD	Director/Board Member	59	31/12/16
Jie Hu BRD	Director/Board Member	49	24/06/19
Shuo Li SEC	Corporate Secretary	34	10/03/20

Members of the board	Title	Age	Since
Jun Yan BRD	Director/Board Member	42	27/11/19
Jin Hao Du CEO	Chief Executive Officer	70	21/03/04
Rong Gang Xie BRD	Director/Board Member	39	27/11/19
Ju Qi BRD	Director/Board Member	72	27/11/19
Jie Hu BRD	Director/Board Member	49	24/06/19
Guo Yang BRD	Director/Board Member	35	31/12/11
Jia Yu Yang BRD	Director/Board Member	45	27/11/19
Chao Lu BRD	Director/Board Member	42	27/11/19
Sheng Tao Zhu BRD	Director/Board Member	46	27/11/19
Jia Qi Jin BRD	Director/Board Member	36	27/03/22

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	450,000,000	171,253,198 ( 38.06 %)	0	38.06 %

Name	Equities	%	Valuation
Hainan Shiyu Investment Management Co., Ltd. 10.88 %	22,499,920	10.88 %	181 M ¥
LAV Management Co., Ltd. 5.894 %	12,187,500	5.894 %	98 M ¥
Yan Qin Zhi 3.183 %	6,581,176	3.183 %	53 M ¥
Xiao Fa Chen 3.168 %	6,551,374	3.168 %	53 M ¥
Aegon-Industrial Fund Management Co., Ltd. 2.922 %	6,041,082	2.922 %	48 M ¥
Penghua Fund Management Co., Ltd. 2.267 %	4,687,379	2.267 %	38 M ¥
Jian Xin Huang 1.820 %	3,762,975	1.820 %	30 M ¥
Wei Sun 1.480 %	3,060,000	1.480 %	25 M ¥
Bosera Asset Management Co., Ltd. 1.340 %	2,770,425	1.340 %	22 M ¥
Yinhua Fund Management Co., Ltd. 0.9967 %	2,060,972	0.9967 %	17 M ¥

Name	Equities	%	Valuation
ARRIVENT BIOPHARMA, INC. 3.81%	1,276,250	3.81%	24,772,013 $

Shanghai Allist Pharmaceuticals Co., Ltd.

26 Lingxiaohua Road Zhoupu Town

201203, Shanghai

http://www.allist.com.cn

address Shanghai Allist Pharmaceuticals Co., Ltd.(688578)

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

62.7

Average target price

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
SHANGHAI ALLIST PHARMACEUTICALS CO., LTD.	+50.50%	3.92B
VERTEX PHARMACEUTICALS INCORPORATED	+14.84%	121B
REGENERON PHARMACEUTICALS, INC.	+18.31%	112B
ARGENX SE	+2.94%	22.72B
BIONTECH SE	-18.26%	20.82B
GENMAB A/S	-18.47%	16.66B
WUXI APPTEC CO., LTD.	-42.36%	16.36B
BEIGENE, LTD.	-14.23%	16.19B
NEUROCRINE BIOSCIENCES, INC.	-0.68%	13.17B
SAREPTA THERAPEUTICS, INC.	+21.87%	11.11B

Bio Therapeutic Drugs